ArticleFrontiers in endocrinology2025
Associations between triglyceride glucose-body mass index and cardiovascular, renal, hepatic and bone biomarkers in patients with type 2 diabetes: a single-center, cross-sectional study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes (T2D) is a prevalent chronic metabolic disorder with significant global health implications, characterized by elevated blood glucose levels and a cluster of cardiometabolic risk factors. The triglyceride glucose-body mass index (TyG-BMI) has emerged as a novel index for assessing insulin resistance (IR) and cardiometabolic risk in T2D patients. Objective: This study aims to investigate the associations between TyG-BMI and the characteristics of cardiovascular, renal, hepatic and bone biomarkers in T2D patients, particularly in the context of Cardiovascular-Kidney-Metabolic (CKM) syndrome. Methods: We conducted a single-center, cross-sectional study involving 2,981 T2D patients. We assessed TyG-BMI and its correlations with the incidence of cardiovascular events, as well as bone, renal, and hepatic biomarkers. The study included 29 clinical characteristics of T2D patients to understand the progressive nature of T2D complications and the potential of TyG-BMI as a risk assessment tool. Results: Preliminary findings suggest a strong association between elevated TyG-BMI and increased trends of cardiovascular, renal, and hepatic, and bone biomarkers in T2D patients. The TyG-BMI showed significantly different trends among quartile subgroups for all identified key assessing indicators, indicating its potential as a convenient and effective tool for risk assessment. Conclusion: The TyG-BMI index is potentially associated with cardiovascular, renal, hepatic, and bone biomarkers in T2D patients. These findings could contribute to the development of strategies for the prevention and translational therapies of related complications in T2D patients, ultimately improving patient outcomes and reducing the burden on healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.